Short Interest in Curis, Inc. (CRIS) Expands By 39.6%

Curis, Inc. (NASDAQ:CRIS) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,276,538 shares, an increase of 39.6% from the October 31st total of 914,102 shares. Based on an average daily trading volume, of 325,109 shares, the days-to-cover ratio is currently 3.9 days. Currently, 4.7% of the company’s stock are sold short.

Several brokerages recently weighed in on CRIS. Zacks Investment Research downgraded Curis from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Cowen restated a “buy” rating on shares of Curis in a research note on Tuesday, September 25th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.33.

Shares of CRIS stock opened at $0.86 on Friday. Curis has a 1-year low of $0.81 and a 1-year high of $5.20. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 38.74. The firm has a market cap of $30.46 million, a P/E ratio of -0.48 and a beta of 1.16.

Curis (NASDAQ:CRIS) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.09. Curis had a negative return on equity of 299.20% and a negative net margin of 316.98%. The firm had revenue of $2.85 million for the quarter, compared to the consensus estimate of $2.38 million. On average, equities research analysts forecast that Curis will post -1.02 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. LMR Partners LLP acquired a new stake in Curis during the 2nd quarter worth about $124,000. JPMorgan Chase & Co. lifted its position in Curis by 780.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 73,954 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 65,554 shares during the period. Paloma Partners Management Co acquired a new stake in Curis during the 2nd quarter worth about $223,000. Millennium Management LLC acquired a new stake in Curis during the 2nd quarter worth about $540,000. Finally, Renaissance Technologies LLC lifted its position in Curis by 30.7% during the 3rd quarter. Renaissance Technologies LLC now owns 620,729 shares of the biotechnology company’s stock worth $1,105,000 after acquiring an additional 145,809 shares during the period. 33.03% of the stock is owned by institutional investors.

WARNING: “Short Interest in Curis, Inc. (CRIS) Expands By 39.6%” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2018/12/02/short-interest-in-curis-inc-cris-expands-by-39-6.html.

Curis Company Profile

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

See Also: How Do I Invest in Dividend Stocks

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit